Growth hormone for in vitro fertilisation (IVF)

Sood, Akanksha; Mohiyiddeen, Gadha; Ahmad, Gaity; Fitzgerald, Cheryl; Watson, Andrew; Mohiyiddeen, Lamiya

doi:10.1002/14651858.cd000099.pub4

Cited by 13 publications

(16 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, studies have shown that growth hormone (GH) can promote sexual maturation and gonadal cell proliferation, improve ovarian response to gonadotropins, facilitate follicular development and maturation, regulate steroid production, enhance endometrial receptivity, as well as promote embryonic quality ( 3 ). It is pointed out that GH supplementation in POR patients can significantly increase the number of oocytes retrieved, the number of embryos available for transfer and the clinical pregnancy rate ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

“…The combination of human menopausal gonadotrophin (HMG) and GH can significantly improve the ovarian responsiveness of patients during controlled ovarian hyperstimulation (COH), reduce the dosage of HMG, and shorten the course of treatment ( 5 ). According to the recent system review, GH reduced the dosage of gonadotropins of POR patients, and its impact on the live birth rate of this group was uncertain ( 3 ). The effect of GH on the mean number of oocytes retrieved in normal responders is uncertain, which further emphasizes the importance of GH in ovarian dysfunction.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Regulation of ovarian function by growth hormone: Potential intervention of ovarian aging

et al. 2023

View full text Add to dashboard Cite

Growth hormone (GH) is mainly secreted by eosinophils of anterior pituitary gland. GH plays an important role in regulating the growth and development of many tissues and cells, so it is used in the treatment of many diseases. In recent years, the regulation of GH on ovarian function has attracted much attention. GH has been applied in controlled ovarian hyperstimulation, particularly in the patients with advanced age, diminished ovarian reserve (DOR) and poor ovarian response (POR). GH can directly bind to the growth hormone receptor (GHR) on the ovary to promote the growth, maturation and ovulation of follicles, as well as to inhibit follicular atresia. GH so as to promote the occurrence of early follicles, enhance the sensitivity of follicles to gonadotropins, accelerate the maturation of oocyte nucleus, improve mitochondrial activity and the quality of oocytes through the insulin-like growth factor (IGF) system, which is an indirect regulation. The deep-seated effects of GH on human reproduction and ovarian aging need further basic research and clinical practice.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Regulation of ovarian function by growth hormone: Potential intervention of ovarian aging

et al. 2023

View full text Add to dashboard Cite

show abstract

“…However, most patients want to get pregnant with their own gamete in some nations; it is difficult for POR patients to receive donated oocytes due to strict bioethics legislation. Various protocols, including an increase in the starting dose of the gonadotropin [ 4 , 8 , 9 ], addition of recombinant luteinizing hormone (LH) [ 10 , 11 ], combination clomiphene citrate (CC) with gonadotropin [ 12 , 13 ], addition of growth hormone (GH) to a controlled ovarian stimulation protocol for patients with POR [ 14 ], and DHEA adjuvant therapy [ 15 ], have been tested in attempts to increase the pregnancy rates in patients with POR; however, none of the strategies has proved effective among the poor responders.…”

Section: Introductionmentioning

confidence: 99%

Accumulated Vitrified Embryos Could Be a Method for Increasing Pregnancy Rates in Patients with Poor Ovarian Response

Shin

Kwon

Choi

et al. 2022

JCM

View full text Add to dashboard Cite

We aimed to assess the efficacy of accumulated embryo transfer (ACC-ET) through several controlled ovarian hyperstimulation (COS) cycles to increase the rates of pregnancy in patients with poor ovarian response (POR). We retrospectively reviewed the medical records of 588 patients with POR under 43-years old who underwent embryo transfer from January 2010 to December 2015. We compared the pregnancy rate (PR), clinical pregnancy rate (CPR), and live birth rate (LBR) between ACC-ET (frozen-thawed: 47; fresh + frozen-thawed: 24) group (n = 71) and fresh ET groups (n = 517). Characteristics of ACC-ET patients were similar to those of fresh ET groups (Age: 38.1 ± 3.5 vs. 38.2 ± 3.7, p = 0.88; Anti Müllerian Hormone (AMH; ng/mL): 0.5 ± 0.4 vs. 0.6 ± 0.6, p = 0.38; follicle stimulating hormone (FSH: mIU/mL): 11.9 ± 8.0 vs. 10.8 ± 9.0, p = 0.35). The total number of transferred embryos (3.1 ± 0.9 vs. 1.5 ± 0.7, p = 0.00), PR (29.6% (21/71) vs. 18.8% (97/517), p = 0.040), and CPR (23.5% (16/68) vs. 14.0% (71/508) p = 0.047) were significantly higher in the ACC-ET group than in the fresh ET group. In addition, PR, CPR, and LBR increased with the number of ET in the fresh ET group. However, there were no significant differences observed in LBR between ACC-ET and fresh ET groups (14.9% (10/67) vs. 9.8% (50/508), p = 0.203). From our knowledge, there is no clinical evidence reported to prove that transfer of multiple embryos of adequate quality obtained through multiple cycles can compensate for the limited number of retrieved oocytes from POR patients. We concluded that ACC-ET from several COS cycles could be an alternative method to increase PR and CPR in <43-year-old patients with POR.

show abstract

“…GH replacement is currently used as adjuvant therapy in patients with a poor ovarian response to controlled ovarian hyperstimulation protocols as per the Bologna criteria [14][15][16][17] . A novel Cochrane metaanalysis, which includes 16 randomized controlled trials about GH role in in vitro fertilization (IVF), concluded that the use of adjuvant GH in IVF treatment protocols slightly increases the number of oocytes retrieved and pregnancy rates in poor responders, while there is an uncertain effect on live birth rates in this group 18 . Although GH has been shown to influence ovarian function, its mechanism of action on OR and relationship with serum GH levels and OR markers of patients with DOR remain ambiguous.…”

Section: Introductionmentioning

confidence: 99%

Büyüme hormonu seviyeleri ile over rezervleri arasındaki ilişki

Duzok

Aslan

KOSAN

et al. 2022

Cukurova Medical Journal

View full text Add to dashboard Cite

Öz Purpose:The aim of this study was to investigate the relationship between serum anti mullerian hormone levels and serum growth hormone levels in patients with diminished ovarian reserve and unexplained infertility who are planned for in vitro fertilization. Materials and Methods: This prospective cohort study includes 154 women and comprises three study groups which include infertile women with diminished ovarian reserve (Group I), women with unexplained infertility (Group II) and healthy women (Group III) as control group. Prospectively recorded patient data comprehended age, body mass index (BMI), antral follicle count (AFC), gravidity and parity, education, occupation, smoking and alcohol use, and laboratory results (Anti-Mullerian hormone (AMH), Growth Hormone (GH), Follicle-Stimulating hormone, Luteinizing Hormone and Estradiol). Results:The study population consisted of 154 subjects, 52 in Group-I, 52 in Group-II, and 50 in Group-III. The mean women age was higher in DOR group than the other two groups (Respectively with quartiles; 35.5(25-40), 29.5(20-38), 33(19-39)). The other demographic parameters were similar between the groups. Median serum AMH levels was lower in DOR group. Growth hormone levels were similar between the groups.. Conclusion: Our results show that growth hormone has no relationship between ovarian reserve markers. Although lack of relation with ovarian reserve, it's widely known that GH plays major role in granulosa cell function.Amaç: Bu çalışmanın amacı düşük over rezervi ve açıklanamayan infertilite sebebi ile in-vitro fertilizasyon uygulanacak hastalarda serum Anti-Mulleryen hormon seviyeleri ile büyüme hormonu seviyeleri arasındaki ilişkiyi araştırmaktır. Gereç ve Yöntem: Bu prospektif kohort çalışması 154 kadını içermektedir. Kadınlar üç ana grup altında incelenmiştir. Grup 1; düşük over rezervi (DOR) nedeni ile, Grup-2 ise açıklanamayan infertilite nedeni ile IVF-ICSI (in vitro fertilizasyon, intrasitoplazmik sperm enjeksiyonu) tedavisi uygulanan kadınlardan, Grup-3 ise sağlıklı kadınlardan oluşmaktadır. Hasta verileri prospektif olarak kaydedilmiş olup, yaş vücut kitle indeksi, antral folikül sayısı, gravida, parite, eğitim, meslek, sigara ve alkol kullanımı ve laboratuvar sonuçları (anti-mullerian hormon (AMH), Büyüme hormonu (GH), folikül sitmulan hormon, luteinizan hormon ve estradiol). Bulgular: 154 kadından oluşan çalışma popülasyonu; Grup-1 de 52, Grup-2 de 52 ve Grup-3 de 50 kadın olmak üzere gruplandırılmıştır. Ortalama kadın yaşı Grup-1 de diğer iki gruba göre daha yüksek bulunmuştur (Sırasıyla, medyan ve çeyrek değerleri ile, 35.5 (25-40), 29.5 (20-38), 33 (19-39). Diğer demografik veriler her üç grup arasında benzer bulunurken, serum AMH medyan değerleri Grup-1 de daha düşük bulunmuş ancak büyüme hormon seviyeleri üç grup arasında benzer olarak saptanmıştır. Sonuç: Bu çalışma, serum büyüme hormonu ve over rezerv belirteçleri arasında herhangi bir korelasyon olmadığını göstermiştir. Her ne kadar over rezervi ile GH arasında korelasyon gözlenmese de büyüme hormonu...

show abstract

Growth hormone for in vitro fertilisation (IVF)

Cited by 13 publications

References 76 publications

Regulation of ovarian function by growth hormone: Potential intervention of ovarian aging

Regulation of ovarian function by growth hormone: Potential intervention of ovarian aging

Accumulated Vitrified Embryos Could Be a Method for Increasing Pregnancy Rates in Patients with Poor Ovarian Response

Büyüme hormonu seviyeleri ile over rezervleri arasındaki ilişki

Contact Info

Product

Resources

About